Testing SG after T-DXd in ER+/HER2-low metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a different chemotherapy drug, called sacituzumab govitecan (SG), can help people with ER+/HER2-low metastatic breast cancer who have already been treated with trastuzumab deruxtecan (T-DXd). It also looks at genetic markers in your tumor to predict who might benefit from SG.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ER-positive, HER2-low breast cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery.
- You have already received hormone therapy plus a CDK4/6 inhibitor, and then trastuzumab deruxtecan (T-DXd) as your last chemotherapy before this trial.
- Your tumor can be safely biopsied (a small sample taken with a needle) for genetic testing.
- You are in good enough health to be up and about at least half the day (ECOG 0-2).
- Your blood counts, kidney, and liver function are within acceptable ranges.
- You do not have active, uncontrolled brain metastases, and any prior brain metastases are stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This study follows patients with breast cancer that has spread to the brain and who have already received the drug Sacituzumab Govitecan (SG). The goal is to learn how well SG works in real-world settings and to see how patients are doing over time.
This trial tests different sequences of antibody-drug conjugates (a type of targeted chemotherapy) for people with ER-positive, HER2-low or ultra-low metastatic breast cancer that has stopped responding to hormone therapy and has progressed on Enhertu. You must have had 1–4 prior chemotherapies for metastatic disease.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This study tests whether giving the drug sacituzumab govitecan together with atropine reduces side effects and improves tolerability in people with advanced breast cancer. You may be eligible if you have either triple-negative or hormone receptor-positive, HER2-negative breast cancer that hasn't responded to previous treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.